

Novavax Investor Relations

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi's 12th Annual Biotech Conference.

Conference details are as follows:

Date: Thursday, September 7, 2017

Location: Mandarin Oriental hotel, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Investor Relations

Novavax, Inc. Andrea N. Flynn, Ph.D.

Director, Investor Relations

ir@novavax.com

240-268-2000

Westwicke Partners

John Woolford

john.woolford@westwicke.com

443-213-0506

Media

Russo Partners, LLC

David Schull

Maggie Beller

david.schull@russopartnersllc.com

maggie.beller@russopartnersllc.com

212-845-4271

<https://ir.novavax.com/2017-09-05-Novavax-to-Participate-in-the-Citi-12th-Annual-Biotech-Conference>